Valuation : Genovis AB

Market Cap 1.4B 146M 126M 118M 108M 201M 13.85B 202M 542M 7.08B 548M 536M 22.52B P/E 2026 *
65.9x
P/E 2027 * 41.5x
Enterprise Value 1.29B 134M 116M 109M 99.26M 185M 12.75B 186M 499M 6.52B 505M 494M 20.74B EV / Sales 2026 *
8.75x
EV / Sales 2027 * 6.77x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.58%
1 week-3.04%
Current month-6.32%
1 month+4.80%
3 months+6.96%
6 months+24.40%
Current year-2.35%
1 week 20.35
Extreme 20.35
22.05
1 month 19
Extreme 19
22.8
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
25.65
3 years 15.64
Extreme 15.64
54.9
5 years 15.64
Extreme 15.64
90
10 years 2.03
Extreme 2.03
90
Manager TitleAgeSince
Chief Executive Officer 55 2015-05-04
Director of Finance/CFO 42 2026-07-31
Chief Tech/Sci/R&D Officer 42 2016-12-31
Director TitleAgeSince
Director/Board Member 77 2013-12-31
Director/Board Member 65 2018-12-31
Chairman 74 2020-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
5/15/26 Buy 4,146 0.0063%
2/24/26 Buy

Chief Financial Officer

3,137 0.0047%
2/24/26 Buy

Chief Financial Officer

2,470 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-2.58%-3.04%-9.78%-61.57% 150M
-0.27%-2.09%+167.56%+377.40% 21.66B
-0.69%-4.95%-36.74%-21.75% 9.93B
+4.71%+9.37%+370.93%+38.51% 8.16B
-1.00%+0.16%-28.70% - 7.08B
-0.52%-0.44%+87.28%+51.27% 6.59B
-2.12%-1.68%-26.90%-19.34% 5.96B
-3.51%-2.89%+70.20%+84.91% 4.35B
-0.57%-2.93%-10.22%-19.86% 4.26B
-0.86%-2.60%-23.91%-29.78% 2.77B
Average -0.74%-1.44%+55.97%+44.42% 7.09B
Weighted average by Cap. -0.25%-0.93%+94.45%+136.12%

Financials

2026 *2027 *
Net sales 147M 15.36M 13.21M 12.43M 11.34M 21.17M 1.46B 21.27M 56.97M 744M 57.69M 56.43M 2.37B 185M 19.35M 16.64M 15.65M 14.28M 26.66M 1.83B 26.79M 71.75M 938M 72.66M 71.07M 2.98B
Net income 15.7M 1.64M 1.41M 1.33M 1.21M 2.26M 155M 2.27M 6.07M 79.38M 6.15M 6.02M 253M 33.6M 3.51M 3.01M 2.84M 2.59M 4.83M 332M 4.85M 13M 170M 13.16M 12.88M 541M
Net Debt -111M -11.58M -9.96M -9.37M -8.55M -15.95M -1.1B -16.04M -42.94M -561M -43.49M -42.54M -1.79B -145M -15.13M -13.01M -12.24M -11.17M -20.84M -1.43B -20.95M -56.1M -733M -56.81M -55.57M -2.33B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
26-09-08 SEK 20.75 -2.58% 192,004
26-09-07 SEK 21.30 +1.91% 170,476
26-09-04 SEK 20.90 -2.79% 47,953
26-09-03 SEK 21.50 +1.90% 452,685
26-09-02 SEK 21.10 -1.40% 79,242
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20.75SEK
Average target price
33.00SEK
Spread / Average Target
+59.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!